Immunovant (IMVT) PT Lowered to $33 at Stifel, 'We are buying'
Tweet Send to a Friend
Stifel analyst Derek Archila lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $54.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
